1. Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
   Babli Khatun et al, 2021, Current Cancer Therapy Reviews CrossRef
2. Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
   Jie Zhang et al, 2022, Journal of Medicinal Chemistry CrossRef
3. Wnt/β-catenin Signaling Inhibitors
   Xun Zhang et al, 2023, Current Topics in Medicinal Chemistry CrossRef
4. Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights
   Sonal Patel et al, 2019, Frontiers in Immunology CrossRef
5. Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells
   Nuha Almasoud et al, 2020, Scientific Reports CrossRef
6. Molecular docking, pharmacokinetic prediction and molecular dynamics simulations of tankyrase inhibitor compounds with the protein glucokinase, induced in the development of diabetes
   Jihane Khamlich et al, 2024, Journal of Biomolecular Structure and Dynamics CrossRef
7. Unravelling the Mechanistic Role of Quinazolinone Pharmacophore in the Inhibitory Activity of Bis-quinazolinone Derivative on Tankyrase-1 in the Treatment of Colorectal Cancer (CRC) and Non-small Cell Lung Cancer (NSCLC): A Computational Approach
   Felix O. Okunlola et al, 2022, Cell Biochemistry and Biophysics CrossRef
8. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies
   Xylia Q. Peters et al, 2020, Anti-Cancer Agents in Medicinal Chemistry CrossRef
9. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer
   Prasanna Anjaneyulu Yakkala et al, 2024, Expert Opinion on Therapeutic Targets CrossRef
10. TFEB; Beyond Its Role as an Autophagy and Lysosomes Regulator
    Berenice Franco-Juárez et al, 2022, Cells CrossRef
11. From PARP1 to TNKS2 Inhibition: A Structure-Based Approach
    Stefano Tomassi et al, 2020, ACS Medicinal Chemistry Letters CrossRef
12. Poly-ADP ribosylation of p21 by tankyrases promotes p21 degradation and regulates cell cycle progression
    Misun Jung et al, 2022, Biochemical Journal CrossRef
13. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
    Daniel Harrision et al, 2020, Frontiers in Molecular Biosciences CrossRef
14. Tankyrase: a promising therapeutic target with pleiotropic action
    Vrunda Sagathia et al, 2023, Naunyn-Schmiedeberg's Archives of Pharmacology CrossRef
15. A New Synthesis of Poly Heterocyclic Compounds Containing [1,2,4]triazolo and [1,2,3,4]tetrazolo Moieties and their DFT Study as Expected Anti-cancer Reagents
    El-sayed M. Abdelrehim et al, 2020, Current Organic Synthesis CrossRef
16. Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies
    Zachary S. Dovey et al, 2021, Cancer Reports CrossRef
17. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities
    Esteban Zamudio-Martinez et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef
18. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor
    Jo Waaler et al, 2020, Journal of Medicinal Chemistry CrossRef
19. Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications
    Asim Rizvi et al, 2021, European Journal of Pharmacology CrossRef
20. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy
    Xylia Q. Peters et al, 2022, Cell Biochemistry and Biophysics CrossRef